SCHEMBL24257853

SCHEMBL24257853

CCOC(=O)CNC(=O)c1ncc(-c2cccc(Cl)c2)c(C2CC2)c1OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VEGFA P15692 4/20 0.45
FLT1 P17948 4/20 0.45
EGLN1 Q9GZT9 4/20 0.45
EGLN3 Q9H6Z9 4/20 0.45
TET3 O43151 1/20 0.41
BBOX1 O75936 1/20 0.41
ASPH Q12797 1/20 0.41
TET2 Q6N021 1/20 0.41
KDM8 Q8N371 1/20 0.41
OGFOD1 Q8N543 1/20 0.41
TET1 Q8NFU7 1/20 0.41
HIF1AN Q9NWT6 1/20 0.41
GPR119 Q8TDV5 1/20 0.40
MAPT P10636 4/20 0.39
KMT2A Q03164 4/20 0.39
LMNA P02545 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 2/20 0.38
PPID Q08752 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30452435 1.00 VEGFA (0.45) VEGFAFLT1EGLN1EGLN3TET3
SCHEMBL24257835 0.88 VEGFA (0.49) VEGFAFLT1EGLN1EGLN3TET3
SCHEMBL30452770 0.88 VEGFA (0.49) VEGFAFLT1EGLN1EGLN3TET3
SCHEMBL24257642 0.86 EGLN1 (0.52) VEGFAFLT1EGLN1EGLN3TET3
SCHEMBL30452626 0.86 EGLN1 (0.52) VEGFAFLT1EGLN1EGLN3TET3
SCHEMBL24257604 0.83 PTGER1 (0.44) L3MBTL1FABP4PLA2G1BHTTATG4B
SCHEMBL30546880 0.83 PTGER1 (0.44) L3MBTL1FABP4PLA2G1BHTTATG4B
SCHEMBL34467306 0.80 EGLN1 (0.58) VEGFAFLT1EGLN1EGLN3TET3
SCHEMBL23501771 0.80 EGLN1 (0.58) VEGFAFLT1EGLN1EGLN3TET3
SCHEMBL30452288 0.79 VEGFA (0.47) VEGFAFLT1EGLN1EGLN3TET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 VEGFA 1862/4885FLT1 414/4885EGLN1 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.